Skip to Content

Posts tagged with "Cancer"

  • Cancer

    Possibly The Most Bungled Clinical Trial Ever?

    I think the way to do this one is send you right to the company’s press release. The way it’s written is hard to improve on; the opening paragraph is like reading a compressed horror novel. It has other virtues, though – there are a couple of odd subject/verb disagreements along the way: “All patient samples… Read More
  • Cancer

    Antibiotics: Not As Easy As They Say

    Since we were just talking yesterday about antibiotics and the misconceptions that people have about them, this is an appropriate time to take a look at an article in the popular press about antibiotic discovery. ( counts as “popular press”, for sure). The article focuses on the work of Brian Murphy at UI-Chicago, who’s do… Read More
  • Business and Markets

    Approvals (and Otherwise) in Oncology

    There have been several big up-or-down moves in oncology drug development the last few days. J&J got unexpectedly early approval for their antibody Darzalex (daratumumab). Originally developed by Genmab, this one is anti-CD38, which is of especial importance in leukemia and myeloma, and the FDA has approved it for multiple myeloma. There’ Read More
  • Cancer

    Another Funny-Looking Structure Comes Through

    Here’s one that I certainly wouldn’t have thought about doing. This recent paper in ACS Medicinal Chemistry Letters describes changing the substituents off the core of a PAK1 inhibitor. Nothing too interesting about that, you’d think: the inhibitor itself is one of your standard-looking kinase inhibitor sausage strings of heteroar… Read More
  • Cancer

    Revolutionary Miracle Breakthrough Cures

    Anyone who knows anything about drug research knows to beware terms like “miracle” or “breakthrough” when used to describe a possible new treatment. There are such things, but they’re out numbered by the press releases and clueless reports that describe every other result as an amazing advance in human knowledge. There… Read More
  • Cancer

    Looking Back at Sutent’s Development: Problems or Not?

    Here’s a report on the preclinical development of Sutent (sunitinib). The authors did a retrospective analysis of all the published studies, and found a number of problems. It should be noted that these are definitely not limited to just this drug – in fact, the authors are explicitly extending their conclusion to a lot of… Read More
  • Cancer

    Artificial Intelligence, You Say?

    Here’s a story from the Telegraph about a small company (Berg Pharmaceuticals), whose headline certainly got my attention: “Cancer drug development time halved thanks to artificial intelligence”. That set off some alarm bells for me, and not because I fear being replaced by a bearded AI quoting mispronounced Latin tags and John Cl… Read More
  • Aging and Lifespan

    A Nobel for DNA Repair

    This year’s Nobel Prize in Chemistry goes to Tomas Lindahl of the Crick Institute, Paul Modrich of Duke/Howard Hughes Medical Institue and Aziz Sancar of UNC – Chapel Hill, for mechanisms of DNA repair. Here’s the press release, and here (PDF) is the detailed scientific background from the Nobel committee. This is not a prize th… Read More
  • Business and Markets

    One of Those “See You in Court” Moments

    Here’s a messy situation that’s playing out in court:  Incyte Corporation sued Flexus Biosciences, its CEO Terry Rosen and its president and research director Juan Jaen, on Sept. 4 in New Castle County Court.      Incyte claims the defendants hired away Jordan Fridman, its chief scientific officer, because he was one of only a few… Read More
  • Cancer

    Verastem Takes a Tumble

    Remember Verastem? Back before the current biotech boom got underway (remember the current biotech boom?), they went public shockingly early. It was not a particularly instructive IPO, since the company was targeting cancer stem cells, and those (as discussed here recently) are the subject of both furious research and furious controversy. They went… Read More